IP Library Granted Patent US 8,524,484
Granted Patent B2
US 8,524,484 · App. 13/412,559 · Granted Sep 3, 2013

Immunogenic minicells and methods of use

Inventors: Roger A. Sabbadini (Lakeside, CA); Neil Berkley (San Diego, CA); Mark W. Surber (San Diego, CA); Matthew J. Giacalone (San Diego, CA)
Assignee: Vaxiion Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,524,484
App. No.
13/412,559
Granted
Sep 3, 2013
Kind
B2
Abstract

The disclosed invention relates to immunogenic minicells cells (anucleated) and their use to induce an immune response from a subject.

Claims (7)

1. A fully intact eubacterial minicell for use in generating an immunogenic response in an animal, comprising a plasmid having an open reading frame encoding a viral antigen of interest, and a eukaryotic expression sequence operably linked to said open reading frame, such that said antigen of interest is expressed in said animal.

2. The minicell of claim 1 , wherein said eukaryotic expression sequence comprises a CMV promoter.

3. The minicell of claim 1 , wherein said eukaryotic expression sequence comprises a stress inducible an inducible promoter.

4. The minicell of claim 1 , wherein said open reading frame is from the genome of a virus.

5. The minicell of claim 4 , where said virus is selected from the group consisting of HIV, smallpox virus, Hepatitis A, Hepatitis B, Hepatitis C, influenza virus, varicella zoster virus, Herpes Simplex Virus, adenovirus, rhinovirus, rinderpest, exhovirus, rotavirus, respiratory syncitial virus, papilloma virus, papova virus, cytomegalovirus, echinovirus, arbovirus, hantavirus, coxsackie virus, mumps virus, measles virus, polio virus, and rubella virus.

6. The minicell of claim 1 , further comprising a prokaryotic expression sequence operably linked to said open reading frame, such that said antigen of interest is expressed in the minicell and the animal.

7. The minicell of claim 6 , wherein said antigen of interest expressed in the minicell is displayed on the surface of the minicell.

Assignments (2)
ORGANIZATION CONVERSION Recorded Apr 30, 2015
From: VAXIION THERAPEUTICS, INC.
To: VAXIION THERAPEUTICS, LLC
Reel/Frame 035557/0644 →
SECURITY AGREEMENT Recorded Mar 21, 2013
From: VAXIION THERAPEUTICS INC.
To: WESTERN STATES INVESTMENT COMPANY, LLC
Reel/Frame 030062/0774 →
Continuity (6)
Division 12133308 · Jun 4, 2008
Division 10832000 · Apr 26, 2004
Continuation In Part 10154951 · May 24, 2002
Provisional Application 60359843 · Feb 25, 2002
Provisional Application 60293566 · May 24, 2001
Related Publication 20120252099A1 · Oct 4, 2012